METALEX COMMENCES DRILLING OF COPPER-NICKEL-COBALT TARGETS AT B3 CLAIM BLOCK IN QUEBEC
KELOWNA, BC, June 9, 2025 /CNW/ - Metalex Ventures Ltd. (TSXV: MTX) (the "Company") announces the start of drilling at its 100% owned B3 claim block in Quebec testing promising geophysical anomalies for copper-nickel-cobalt mineralization.
Claim Block B3 (Copper-Nickel-Cobalt)
The 24,322 hectare B3 claim block was staked due to the Company's heavy mineral and soil-till sampling indicating it contains copper-nickel-cobalt sulphides. Metalex has undertaken a VTEM airborne geophysical survey over its B3 claim block by Geotech Ltd.
The VTEM survey, which included both electromagnetic and magnetic data, was reviewed by SHA Geophysics Inc. Their work indicates that eight of the conductors detected by the electromagnetic survey are thought to likely represent sulphide mineralization. These are shown on Map 1.
Drilling has now commenced on the first of these conductors.
Claim Blocks A1 and A2 (Gold)
When drilling at the B3 copper-nickel-cobalt project is complete Metalex hopes to move the drill to its A1 and A2 claim blocks staked for gold. These claim blocks were staked due to the promising gold and pathfinder element results from detailed heavy mineral sampling of the areas. A VTEM survey over the claim blocks identified several conductive and magnetic anomalies that could be the bedrock source of the gold.
Regional Exploration
The Company also intends to complete follow up heavy mineral sampling on gold anomalies identified by its +/- 10,000 sample regional database in Quebec. 185 gold anomalies thought to reflect bedrock rather than placer sources have been discovered in the survey.
The technical information and results reported here have been reviewed by Mr. Chad Ulansky P.Geo., a Qualified Person under National Instrument 43-101, who is responsible for the technical content of this release.
Signed,
Charles Fipke
Charles Fipke
Chairman
FORWARD LOOKING STATEMENTS: Certain of the statements and information in this press release constitute "forward-looking statements" or "forward-looking information", including statements regarding the expected use of proceeds of the private placement. Further, any statements or information that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "expects", "anticipates", "believes", "plans", "estimates", "intends", "targets", "goals", "forecasts", "objectives", "potential" or variations thereof or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative of any of these terms and similar expressions) are not statements of historical fact and may be forward-looking statements or information. The Company's forward-looking statements and information are based on the assumptions, beliefs, expectations and opinions of management as of the date of this press release, and other than as required by applicable securities laws, the Company does not assume any obligation to update forward-looking statements and information if circumstances or management's assumptions, beliefs, expectations or opinions should change, or changes in any other events affecting such statements or information. For the reasons set forth above, investors should not place undue reliance on forward-looking statements and information.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Metalex Ventures Ltd.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
MedX Announces Final Closing of Non-Brokered Private Placement
MedX Health Corp. (' MedX ' or the ' Company ') (TSX-V: MDX) is pleased to announce that, further to its Press Releases dated April 7, and May 22, 2025, announcing an Initial Closing and further Closing, it has completed a final Closing of the Non-brokered Private Placement to accredited investors originally announced in its Press Release dated February 25, 2025. The Final Closing comprised the issuance of 8,678,571 Units (as described below) and raised cash proceeds of $607,500, bringing the total amount raised in the Placement to $2,063,500. Securities issued are subject to a regulatory 'hold' period of four months and one day from the date of issuance. Under this Non-Brokered Private Placement, the Company issued a total of 29,478,571 Units at $0.07 per Unit ('Unit'). Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant (' Warrant ( s)'), exercisable to purchase One (1) further Common Share at the price of $0.09, during the period of one year commencing on the date of issuance. Three Insiders participated in this Placement to the extent of $500,000, for the acquisition of a total of 7,142,857 Units. In connection with the issuance of Units to those Insiders, the Company relies on exemptions from formal valuation and minority shareholder approval requirements set out in Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (' MI 61-101 '). as (i) the fair market value of the proposed placement to the Insiders does not exceed 25% of the market capitalization of the Company and (ii) the conditions in section 5.7(1)(a), section 5.7(1)(b) and section 5.7(1)(e) of MI 61-101 are met. Qualified agents received total cash commissions of $15,880, (equal to 8% of the gross proceeds received by the Company from the sale of the Units to subscribers introduced by such agent(s)), and 226,857 agent's warrants (' Agent's Warrant(s) ') (equal to 8% of subscriptions introduced by such agent(s)). Each Agent's Warrant, which is non-transferable, entitles the holder to acquire, at the price of CAD$0.07, a unit, comprised of One (1) fully paid Common Share and one (1) non-transferable share purchase warrant (' Agent's Share Purchase Warrant '), entitling the holder to acquire one additional Common Share at the price of CAD$0.09. The Agent's Warrants and any Agent's Share Purchase Warrants that may be issued pursuant to exercise of an Agent's Warrant, if not exercised, will expire one year following the date of issuance. Funds raised in this Placement are being be directed towards continuing development of the Company's leading edge SIAscopy® on DermSecure® telemedicine platform, building out the launch of its technology into the occupational health marketplace, and general corporate purposes. About MedX Health Corp.: MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union and Turkey. Visit This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
National Post
an hour ago
- National Post
MedX Announces Final Closing of Non-Brokered Private Placement
Article content MISSISSAUGA, Ontario — MedX Health Corp. (' MedX ' or the ' Company ') (TSX-V: MDX) is pleased to announce that, further to its Press Releases dated April 7, and May 22, 2025, announcing an Initial Closing and further Closing, it has completed a final Closing of the Non-brokered Private Placement to accredited investors originally announced in its Press Release dated February 25, 2025. The Final Closing comprised the issuance of 8,678,571 Units (as described below) and raised cash proceeds of $607,500, bringing the total amount raised in the Placement to $2,063,500. Securities issued are subject to a regulatory 'hold' period of four months and one day from the date of issuance. Under this Non-Brokered Private Placement, the Company issued a total of 29,478,571 Units at $0.07 per Unit ('Unit'). Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant (' Warrant (s)'), exercisable to purchase One (1) further Common Share at the price of $0.09, during the period of one year commencing on the date of issuance. Three Insiders participated in this Placement to the extent of $500,000, for the acquisition of a total of 7,142,857 Units. In connection with the issuance of Units to those Insiders, the Company relies on exemptions from formal valuation and minority shareholder approval requirements set out in Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (' MI 61-101 '). as (i) the fair market value of the proposed placement to the Insiders does not exceed 25% of the market capitalization of the Company and (ii) the conditions in section 5.7(1)(a), section 5.7(1)(b) and section 5.7(1)(e) of MI 61-101 are met. Article content Qualified agents received total cash commissions of $15,880, (equal to 8% of the gross proceeds received by the Company from the sale of the Units to subscribers introduced by such agent(s)), and 226,857 agent's warrants (' Agent's Warrant(s) ') (equal to 8% of subscriptions introduced by such agent(s)). Each Agent's Warrant, which is non-transferable, entitles the holder to acquire, at the price of CAD$0.07, a unit, comprised of One (1) fully paid Common Share and one (1) non-transferable share purchase warrant (' Agent's Share Purchase Warrant '), entitling the holder to acquire one additional Common Share at the price of CAD$0.09. The Agent's Warrants and any Agent's Share Purchase Warrants that may be issued pursuant to exercise of an Agent's Warrant, if not exercised, will expire one year following the date of issuance. Article content Article content Funds raised in this Placement are being be directed towards continuing development of the Company's leading edge SIAscopy® on DermSecure® telemedicine platform, building out the launch of its technology into the occupational health marketplace, and general corporate purposes. Article content About MedX Health Corp.: Article content MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union and Turkey. Visit Article content This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Article content Article content Article content Article content Article content
Cision Canada
2 hours ago
- Cision Canada
ANNUAL GENERAL MEETING
VANCOUVER, BC, June 9, 2025 /CNW/ - (TSX: AOI) (Nasdaq-Stockholm: AOI) – Meren Energy Inc. ("Meren" or the "Company") confirms that its Annual General Meeting of Shareholders will be held on Thursday, June 12, 2025 at 09:00 am (Pacific Time) at Bennett Jones LLP Fraser Boardroom, Park Place, 666 Burrard Street, Suite 2500, Vancouver V6C 2X8. View PDF version The purpose of the Meeting is as follows: View PDF To receive the consolidated audited financial statements and accompanying management's discussion and analysis of the Company for the year ended December 31, 2024, together with the report of the auditors; To appoint PricewaterhouseCoopers LLP as auditors of the Company to hold office until the next Annual General Meeting, at a remuneration to be fixed by the directors of the Company; To consider and, if deemed advisable, to approve an advisory resolution to accept the Company's approach to executive compensation; and To elect directors to hold office for the ensuing year. The record date for the Annual General Meeting of Shareholders is April 24, 2025. The Notice of Meeting, Management Information Circular, and related meeting materials are available under the Company's profile on SEDAR at and on the Company's website at About Meren Meren is a full-cycle Independent upstream oil and gas company with interests offshore Nigeria, Namibia, South Africa and Equatorial Guinea. Its main assets are producing and development assets in deepwater Nigeria operated by Majors. The Company holds a leading position in the Orange Basin including its effective interest in the Venus light oil project, offshore Namibia, and its direct interest in Block 3B/4B, offshore South Africa. Additional Information This information was submitted for publication, through the agency of the contact persons set out above, at 6:30 p.m. EDT on June 9, 2025. Forward Looking Information Certain statements and information contained herein constitute "forward-looking information" (within the meaning of applicable Canadian securities legislation). Such statements and information (together, "forward-looking statements") relate to future events or the Company's future performance, business prospects or opportunities. All statements other than statements of historical fact may be forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "seek", "anticipate", "plan", "continue", "estimate", "expect, "may", "will", "project", "predict", "potential", "targeting", "intend", "could", "might", "should", "believe" and similar expressions) are not statements of historical fact and may be "forward looking statements". SOURCE Meren Energy Inc.
